Physician profile
Steven Domnitz
NPI 1427096254
$2,370.31
in general payments reported to CMS, 2019-2025
26 companies · $499 in 2025
The $499 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $65.37 · 2021: $326 · 2022: $418 · 2023: $306 · 2024: $185 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $695.75 | 2019-2022 | |
| Applied Medical Resources Corporation | $235.88 | 2021 | |
| Organon LLC | $173.07 | 2022-2025 | Nexplanon |
| Abbvie INC. | $172.11 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $155.47 | 2022-2025 | |
| Astellas Pharma US INC | $125.83 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $111.30 | 2024-2025 | Slynd |
| Hologic Sales and Service, LLC | $106.74 | 2024-2025 | Myosure Tissue Removal Device, Novasure, Fluent Fluid Management System |
| Bayer Healthcare Pharmaceuticals INC. | $93.92 | 2020-2024 | |
| Pfizer INC. | $62.27 | 2019-2023 | |
| Allergan, INC. | $58.01 | 2019-2020 | |
| Agile Therapeutics, INC. | $46.36 | 2023 | Twirla |
| Alydia Health | $40.22 | 2021 | |
| Millicent US INC | $37.21 | 2025 | Femlyv, Femring, Intrarosa |
| Coopersurgical, INC. | $35.77 | 2019-2025 | Sos |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $35.61 | 2024 | Pico 7 |
| Amag Pharmaceuticals, INC. | $32.22 | 2019 | |
| Evofem Biosciences, INC. | $27.62 | 2023-2024 | Phexxi |
| Therapeuticsmd, INC. | $26.48 | 2019-2020 | |
| Lupin INC. | $26.24 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $15.74 | 2023 | Vivjoa |
| Sumitomo Pharma America, INC. | $15.46 | 2025 | Myfembree |
| Merck Sharp & Dohme LLC | $14.67 | 2019 | |
| Myovant Sciences INC. | $14.46 | 2022 | |
| Meditrina | $11.90 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Domnitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.